Clinical Trial Update: Altropane Dose for Imaging Patients With Suspected Parkinson's Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Altropane as an imaging agent for patients with suspected Parkinson disease was terminated. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Movement Disorders
• Parkinson Disease

Drugs mentioned

• Altropane (Altropane)

Snippet

Sponsor: GE Healthcare | Conditions: Parkinson Disease, Movement Disorders | Phase 2 | Status: TERMINATED | Results posted: 2025-07-15